Nivolumab Preserves Quality of Life and Reduces Symptom Progression in Resectable NSCLC, Study Finds
A groundbreaking Phase III trial reveals that nivolumab maintains quality of life and reduces symptom worsening in patients with resectable non-small cell lung cancer, including those with advanced Stage III N2 disease.
A recent Phase III CheckMate 77T trial has demonstrated that perioperative treatment with nivolumab does not negatively impact health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those diagnosed with Stage III N2 disease. The comprehensive analysis, presented at the 2025 World Conference on Lung Cancer (WCLC), confirms that patients receiving nivolumab alongside chemotherapy before surgery maintain their QoL across various stages of treatment.
The study assessed HRQoL using patient-reported outcome measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual analog scale (VAS). Patients were administered either neoadjuvant nivolumab combined with chemotherapy or a placebo with chemotherapy, followed by surgical resection and additional therapy. Results showed over 90% PRO completion rates in all nodal status groups, indicating consistent engagement and reliable data collection.
Dr. Jonathan Spicer of McGill University Health Center highlighted the significance of these findings, emphasizing that maintaining QoL during and after treatment is essential for long-term success. Notably, among Stage III N2 patients, nivolumab significantly reduced the risk of QoL deterioration compared to placebo, with hazard ratios of 0.50 for NSCLC-SAQ and 0.47 for EQ-5D-3L VAS. These benefits were observed in patients undergoing various surgical procedures, including single lobectomy or complete resection.
This research underscores nivolumab's dual role in extending event-free survival and safeguarding patient well-being in early-stage resectable NSCLC, particularly those at higher risk due to N2 nodal involvement. The findings support the integration of perioperative nivolumab into treatment regimens aimed at both improving clinical outcomes and preserving quality of life.
Source: https://medicalxpress.com/news/2025-09-nivolumab-quality-life-symptom-deterioration.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Twin Study Reveals Mitochondria's Role in Regulating Genes Linked to Obesity
Research on Finnish twins uncovers how mitochondrial quantity influences gene activity linked to obesity, shedding light on metabolic mechanisms that contribute to weight gain and potential personalized treatments.
Impact of Federal Cuts on Language Services and Patient Safety Risks
Federal budget cuts are reducing language assistance services for non-English speakers, risking increased medical errors and disparities in healthcare access. Learn how policy changes affect patient safety and community health.
New Evidence Confirms Safety and Efficacy of Lecanemab for Early-Stage Alzheimer’s
Recent studies reaffirm the safety and effectiveness of lecanemab in slowing Alzheimer’s progression, with rare manageable side effects observed in early-stage patients.